Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (311-320 of 703) with videos related to

Pageof 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
NPJ Precision Oncology|May 30, 2026
Distinctive features of the tumor and immune microenvironment in glioblastomaElena Shklovskaya, Bernadette Pedersen, Su Yin Lim, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2019
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncologyLucie Heinzerling, Paolo A Ascierto, Reinhard Dummer, et al.
Oncoimmunology|March 17, 2023
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentationsBenjamin C Park, Sathya Narayanan, Alexander Gavraldis, et al.
Oncotarget|March 9, 2019
Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomasCamelia Quek, Robert V Rawson, Peter M Ferguson, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Pathology|September 5, 2018
Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanomaBenjamin M Allanson, Martin A Weber, Louise A Jackett, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Pathology|March 30, 2016
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingRicardo De Paoli-Iseppi, Peter A Johansson, Alexander M Menzies, et al.
Pageof 71

Showing results (311-320 of 703) with videos related to

Sort By:
Pageof 71
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
NPJ Precision Oncology|May 30, 2026
Distinctive features of the tumor and immune microenvironment in glioblastomaElena Shklovskaya, Bernadette Pedersen, Su Yin Lim, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2019
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncologyLucie Heinzerling, Paolo A Ascierto, Reinhard Dummer, et al.
Oncoimmunology|March 17, 2023
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentationsBenjamin C Park, Sathya Narayanan, Alexander Gavraldis, et al.
Oncotarget|March 9, 2019
Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomasCamelia Quek, Robert V Rawson, Peter M Ferguson, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Pathology|September 5, 2018
Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanomaBenjamin M Allanson, Martin A Weber, Louise A Jackett, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Pathology|March 30, 2016
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingRicardo De Paoli-Iseppi, Peter A Johansson, Alexander M Menzies, et al.
Pageof 71